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Abstract
Introduction: The aim of the study was to explore the distribution of healthy
people with different anti-tumour ability.
Material and methods: Leukocytes were separated by the Ficoll-Hypaque density
gradient centrifugal method. Then they were mixed with A549, MCF-7 and Hela
cells at different ratios. The survival rate for target cells was observed and
counted by Fluoroskan. Immune function for 200 healthy people was analysed
by flow cytometry. 
Results: The results obtained by confocal microscopy revealed that human blood
leukocytes possessed direct anti-tumour activity. The survival rate for tumour
cells was the lowest in the condition of 20:1 ratio of effector cells to target cells.
We speculated that in 200 healthy people the leukocyte capacity for killing MCF-7
cells is stronger than the leukocyte capacity for killing A549 cells and Hela 
cells. We also found that the distribution for 200 healthy people with different
anti-tumour ability was different for different tumour cells. The number of
healthy people with the strongest anti-tumour ability was highest when the
target cells were MCF-7 cells. Moreover, the survival of A549, MCF-7 and Hela
cells was correlated with T, B and NK lymphocytes. 
Conclusions: From the above, we can select healthy individuals with strong anti-
tumour ability as anti-tumour donors according to their distribution with different
anti-tumour ability, which opened up a new direction for fighting human cancer.
Key words: innate immunity, tumour, leukocytes, polymorphonuclear leucocytes,
distribution, healthy people. 
Introduction
Cancer is one of the most serious diseases that threaten human beings
today. More than 5 million people each year die of multiple types of cancer,
including liver, lung, breast, prostate cancers, etc. At present, the incidence
of all kinds of cancer (both squamous cell and adenocarcinoma) appears
to be increasing. It is estimated that the number of cancer deaths globally
each year could double by 2020.
There are many tumours resisting conventional chemotherapy and
radiotherapy, and at present these tumours indicate a poor prognosis.
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Thus more effective immunotherapy is needed,
especially for advanced tumours. There are two
functional systems in tumour immunotherapy:
innate immunity and acquired immunity [1-4].
Innate immunity, also known as natural immunity,
is the condition where the body has the inherent
ability for resistance against invasion of pathogens
and removal of foreign bodies in vivo. Innate
immunity involves a large number of different cell
populations such as epithelial cells, monocytes,
macrophages, dendritic cells, polymorphonuclear
leucocytes (PMN), and natural killer (NK) cells. The
traditional view supported the idea that innate
immunity and acquired immunity (i.e., adaptive
immunity, specific immunity) represented two
separate types of immunity. They have different
evolution, development, mechanism of action and
characteristics. Innate immunity is the first
protective line in resisting the pathogenic
microorganism. It can initiate and participate in the
acquired immune response, and acquired immunity
may produce identification and subsequent activity
against specific pathogens (antigens) in long-term
exposure to exogenous pathogens. Due to its
specific characteristics, such as memory, the
acquired immune response has always been
regarded as the body's main anti-tumour immune
response mechanism. However, innate immunity
has been studied widely in an anti-infective field
instead of an anti-cancer field due to its
instantaneous character and lack of memory, which
is different from acquired immunity.
Recently, Cui et al. discovered that SR/CR 
mice have these abilities with resistance to 
S180-induced ascites (spontaneous regression, SR)
or remained ascites-free after repeated injections
of S180 cells (complete resistance, CR) [5]. 
Further study has shown that macrophages,
polymorphonuclear leucocytes (PMN) and natural
killer cells play an important role in attacking
tumour cells [5-8].
The PMN, monocyte-macrophages and NK cells
belong to innate immune cells. Although they start
to participate in and regulate the acquired immune
response by assisting T lymphocytes to recognize
tumour cells, they themselves have a certain anti-
tumour capacity. It has been reported that this
capability is inherent and does not vary from person
to person. In a series of anti-tumour studies on
SR/CR mice, Cui found that this natural anti-tumour
ability is not only genetic, but is also transferred,
which provides a new strategy for tumour
immunotherapy. 
Can we discover the same cancer-resistance trait
in leukocytes of healthy people? How do we obtain
their immune cells? How do we choose the best
cancer-resistant people? Will individual differences
for healthy people result in anti-tumour ability
differences among them? Is the difference in cancer
resistance related to the T lymphocyte acquired
immunity? 
In order to answer the above questions, we
analysed blood samples from 200 healthy people
and explored the distribution of healthy people with
different anti-tumour ability in order to open up
a new direction for fighting human cancer. 
Material and methods
Cell lines
A549, MCF-7 and Hela cell lines were purchased
from the American Type Culture Collection and
propagated in DMEM (Dulbecco’s Modified Eagle’s
Medium, Gibco) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 units/ml
penicillin and 100 mg/ml streptomycin. Cultures
were maintained at 37°C in a humidified
atmosphere containing 95% air and 5% carbon
dioxide. 
Isolation of human peripheral blood leukocytes
and their percentage analyses 
Blood samples of 200 healthy people were
provided by the Chinese PLA General Hospital. The
fresh blood samples were first diluted 1:1 with
phosphate-buffered saline (PBS) and then added
to a Ficoll-Hypaque density gradient solution. The
suspension was centrifuged at 400 g for 15 min at
room temperature. PMN were harvested and mixed
with 2 ml of H2O and 1 ml of PBS for 10 min to
destroy red blood cells. The suspension was then
centrifuged at 400 g for 3 min at RT. Cells were re-
suspended in PBS and the cell concentration was
adjusted at a density of 2.5 × 105/ml. Then, they
were labelled with specific anti-CD45 (Beckman) to
the cell surface according to standard procedures
recommended by the manufacturer and analysed
on a Beckman Coulter EPICS XL (Beckman Coulter,
Miami FL, USA).    
Tumour cells labelled with CFSE 
A 5 mM stock solution of carboxyfluorescein
succinimidyl ester (CFSE) (Invitrogen) was prepared
by dissolving 500 µg of CFSE into 180 µl of dimethyl
sulfoxide. Tumour cells were plated at a density of
8 × 104 cells per well in 24-well plates. When they
were grown overnight to 80% confluence, tumour
cells were suspended in PBS/0.1% BSA at a density
of 1 × 106 cells/ml. Then they were incubated with
2 µl of 5 mM CFSE at 37°C for 10 min, which
resulted in a final concentration of 10 µM. The
reaction was stopped by adding 5V ice-cold culture
medium. They were centrifuged and washed twice
with ice-cold PBS. After that, they were observed
under a laser scanning confocal microscope.
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In vitro assays of target cell survival rate
Tumour cells labelled with CFSE were seeded in
96-well plates, and then leukocytes were added.
The effector cells were mixed with target cells at
a ratio of 5 : 1, 10 : 1 and 20 : 1, and they were
incubated for 48 h at 37°C in a humidified
atmosphere containing 95% air and 5% carbon
dioxide. The survival rate for target cells was
observed and counted by Fluoroskan.
Immune function analyses by flow cytometry
Whole blood samples were taken using sterile
tubes with EDTA anticoagulant. First, 10 µl of CD45-
FITC/CD4-RD1/CD8-ECD/CD3-PC5 or CD45-FITC/
CD56-RD1/C19-ECD/CD3-PC5 was added to each
sample label test tube, and 100 µl of whole blood
samples were added to it after adjusting the white
cell count to approximately 5 × 109 cells/l. Then they
were incubated in the dark at room temperature
for 20 min 500 µl of OptiLyse C lysing solution was
added to whole blood samples and vortex mixed.
They were incubated at room temperature for 
10 min. Finally, 500 µl of PBS was added followed
by brief vortex mixing. After 10 min, cells were
analysed by flow cytometry. 
Statistical analysis
All experiments were repeated a minimum of
three times. The data are presented as means ± SD.
Statistics were calculated using SPSS 10.0 software
for all analyses. Statistical differences between the
two groups were analysed using the t test. P values
less than 0.05 were considered significant. 
Results
The analysis of leukocyte subsets and purity
by flow cytometry
To determine the cell separated effect using the
Ficoll-Hypaque density gradient centrifugal
method, leukocyte subsets and purity from
peripheral blood of healthy people were analysed
by flow cytometry. The results demonstrated that
three groups of cells can be divided well by CD45
labelling. They were lymphocytes, monocytes, and
neutrophils (Figure 1. A). The percentage of
lymphocytes was 40.02%, monocytes 7.30% and
neutrophils 51.18% (Figure 1. B). 
In vitro assays of target cells’ survival rate
To address the question of whether human
leukocytes have the cancer-resistance trait, like the
SR/CR mouse model, we isolated leukocytes from
healthy people and mixed them with A549 (human
lung carcinoma epithelial cell line), MCF-7 (human
breast adenocarcinoma cell line) and Hela (cervix
adenocarcinoma epithelial cell line) cells at different
ratios. The survival rate for target cells was
observed and counted by Fluoroskan. 
The results showed that the survival rate for
tumour cells was different for different ratios of
effector cells to target cells (Figures 2-4). For A549
cells, we found that the survival rate for A549 cells
decreased when the ratio of effector cells to target
cells increased. When the ratio of effector cells to
target cells was 5 : 1, it was not obviously different
than control. In the condition of a 20 : 1 ratio of
effector cells to target cells, the survival rate for A549
cells was the lowest. From Figure 2. D, we can see
A549 cells’ lysis by infiltrating leukocytes. The same
results were obtained from Hela and MCF-7 cells. 
Target cells’ survival rate statistics at different
ratios of effector cells to target cells 
The effector cells are leukocytes from peripheral
blood of healthy people which were isolated by
Ficoll-Hypaque density gradient solution. The target
cells were A549, MCF-7 and Hela cells. The target
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Figure 1. Flow cytometric analysis of peripheral blood
from healthy people after CD45 labelling. The results
demonstrated that lymphocytes, monocytes and
neutrophils can be divided well by CD45 labelling (A).
The percentage of lymphocytes is 40.02%, mono  -
cytes 7.30%, neutrophils 51.18% (B)
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Figure 3. Survival rate for Hela cells. After separating 200 blood donors’ leukocytes with the Ficoll-Hypaque density
gradient method, tumour cells labelled with CFSE were mixed with leukocytes at different ratios and incubated for
48 h at 37°C. The images were obtained with confocal microscopy (Fluoroskan). (A) Hela cells labelled with CFSE; 
(B) The ratio of effector cells to Hela cells was 5 : 1; (C) The ratio of effector cells to Hela cells was 10 : 1; (D) The ratio
of effector cells to Hela cells was 20 : 1. Scale bars: 50 µm
Figure 2. Survival rate for A549 cells. After separating 200 blood donors’ leukocytes with the Ficoll-Hypaque density
gradient method, tumour cells labelled with CFSE were mixed with leukocytes at different ratios and incubated for
48 h at 37°C. The images were obtained with confocal microscopy (Fluoroskan). (A) A549 cells labelled with CFSE; 
(B) The ratio of effector cells to A549 cells was 5 : 1; (C) The ratio of effector cells to A549 cells was 10 : 1; (D) The ratio
of effector cells to A549 cells was 20 : 1. Scale bars: 50 µm
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cells were labelled with CFSE as above. Then the
effector cells were mixed with target cells at
different ratios. They were incubated for 48 h at
37°C. To evaluate the effect of leukocytes killing
target cells, we counted the survival rate of target
cells at different ratios of effector cells to target
cells. 
The results showed that the survival rate for
target cells was the lowest in the condition of 
a 20 : 1 ratio of effector cells to target cells. The
survival rate for A549 was 0.64 ±0.12. The survival
rate for MCF-7 cell was 0.38 ±0.17 (Figure 5). From
the above, we can speculate that in 200 healthy
people the capacity of leukocytes for killing MCF-7
cells is stronger than the capacity of leukocytes for
Figure 4. Survival rate for MCF-7 cells. After separating 200 blood donors’ leukocytes with the Ficoll-Hypaque density
gradient method, tumour cells labelled with CFSE were mixed with leukocytes at different ratios and incubated for
48 h at 37°C. The images were obtained with confocal microscopy (Fluoroskan). (A) MCF-7 cells labelled with CFSE;
(B) The ratio of effector cells to MCF-7 cells was 5 : 1; (C) The ratio of effector cells to MCF-7 cells was 10:1; (D) The ratio
of effector cells to MCF-7 cells was 20 : 1. Scale bars: 50 µm
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Tumor cells at different ratio with effector cells to target cells
Figure 5. The survival rate for target cells was
counted by Fluoroskan at different ratios for effector
cells and target cells. The results indicated that the
survival rate for tumour cells was different for
different effector cells with the same ratio 
(**P < 0.01). In the condition of a 20 : 1 ratio of
effector cells to target cells, the survival rate for
tumour cells was the lowest. The survival rate for
A549 was 0.64 ±0.12. The survival rate for MCF-7
cells was 0.38 ±0.17. This showed that the MCF-7 cell
killing capacity of leukocytes is stronger than the
killing capacity for A549 cells. Leukocytes from
healthy people act differently in their effect on
different tumour cells
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killing A549 cells. This is consistent with the results
of Fig. 2-4. Furthermore, leukocytes of healthy
people act differently in their effect on different
tumour cells.
Distribution of 200 healthy people with
different anti-tumour ability 
For A549, MCF-7 and Hela cells, in the condition
of a 20 : 1 ratio of effector cells to target cells, the
distribution of 200 healthy people with different
anti-tumour ability is shown in Figure 6. In
accordance with their different capacity for killing
tumour cells, the 200 healthy people were divided
into three groups, of which group A has the
strongest anti-tumour ability (tumour cell survival
rate 0-30%), group B has medium anti-tumour
ability (tumour cell survival rate 30-70%), and group
C has the weakest anti-tumour ability (tumour cell
survival rate 70-100%). 
For A549 cells, among 200 healthy people, the
number of healthy people with the strongest anti-
tumour ability was 4; the number of healthy people
with medium anti-tumour ability was 140; the
number of healthy people with the weakest anti-
tumour ability was 56. 
For MCF-7 cells, the number of healthy people
with the strongest anti-tumour ability was 60; the
number of healthy people with medium anti-tumour
ability was 135; the number of healthy people with
the weakest anti-tumour ability was 5. 
For Hela cells, the number of healthy people with
the strongest anti-tumour ability was 42; the
number of healthy people with medium anti-tumour
ability was 128; the number of healthy people with
the weakest anti-tumour ability was 30.
Percentage analysis of 200 healthy people with
different anti-tumour ability 
For A549 cells, among 200 healthy people, the
percentage of healthy people with the strongest
anti-tumour ability was 2%; the percentage of
healthy people with medium anti-tumour ability
was 70%; the percentage of healthy people with
the weakest anti-tumour ability was 28%. 
For MCF-7 cells, the percentage of healthy people
with the strongest anti-tumour ability was 30%; the
percentage of healthy people with medium anti-
tumour ability was 67%; the percentage of healthy
people with the weakest anti-tumour ability was 3%. 
For Hela cells, the percentage of healthy people
with the strongest anti-tumour ability was 21%; the
percentage of healthy people with medium anti-
tumour ability was 64%; the percentage of healthy
people with the weakest anti-tumour ability was
15% (Figure 7).
Comparison analysis of target cell survival rate
following leukocyte infiltration for 200 healthy
people of different ages
The 200 healthy people were divided into group
A and group B according to their ages. The age for
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Figure 6. Distribution of 200 healthy people with
different capacity for killing tumour cells. Group A has
the strongest anti-tumour ability (tumour cells’
survival rate is in the range 0-30%), group B has
medium anti-tumour ability (tumour cells’ survival
rate 30-70%), and group C has the weakest anti-
tumour ability (tumour cells’ survival rate 70-100%) 
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Figure 7. Percentage analysis of 200 healthy people with different capacity for killing tumour cells. Group A has the
strongest anti-tumour ability (tumour cells’ survival rate 0-30%), group B has medium anti-tumour ability (tumour
cells’ survival rate 30-70%), and group C has the weakest anti-tumour ability (tumour cells’ survival rate 70-100%) 
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group A was below 20 years, the age for group B
was in the range of 20-25 years, and the age for
group C was over 25 years. As shown in Table I, no
difference was observed in the survival rate for
A549 cells and MCF-7 cells among 200 healthy
people in different age groups. For Hela cells, the
difference in cell survival rate was significant
between group A and group B (P < 0.05).
Correlation analysis between target cell survival
rate following leukocyte infiltration in 200
healthy people and immune function of healthy
people
In order to investigate whether the tumour cell
killing ability of healthy people was related to their
immune function, we analysed the correlation
between target cells’ survival rate after leukocyte
infiltration in 200 healthy people and immune
function in healthy people. 
As shown in Table II, the value of CD3+CD8+ T
lymphocytes was positively related to survival rate
of A549 cells (r = 0.172, P < 0.05); the value of
CD3+CD4+ T lymphocytes was negatively correlated
with survival rate of A549 cells (r = –0.189, P < 0.01);
the value of CD4/CD8 was negatively related to
survival rate of A549 cells (r = –0.188, P < 0.01); the
values of CD3+, CD3+CD4+, CD4/CD8, CD3-CD56+ T
lymphocytes were positively related to survival rate
of MCF-7 cells; CD3–CD56+ B lymphocytes were
negatively related to survival rate of MCF-7 cells.
The value of CD3–CD19+, CD3–CD56+ B lymphocytes
was negatively related to survival rate of Hela cells. 
These findings showed that survival rate of A549,
MCF-7 and Hela cells was correlated with T, B and
NK lymphocytes.
Discussion
The concept of using immune cells from one
person to fight cancer in another person is a very
pertinent topic right now. Dr Cui’s findings
suggested that it may be possible to transfer the
ability to fight cancer between mice. Cui's group
also successfully treated a range of different
cancers in mice by injecting them with granulocytes
from a strain of mice that are completely resistant
to cancer.
All of us have some ability to fight cancer, via
immune cells which can identify and kill tumour
cells, although the extent of these cells’ influence
is not known. Can we discover the same cancer-
resistance trait in leukocytes of healthy people?
How do we get their immune cells? How do we
choose the best cancer-resistant people in healthy
people? In order to answer this question, we
investigated the distribution of 200 healthy people
with different anti-tumour ability. 
We separated leukocyte cells using the Ficoll-
Hypaque density gradient centrifugal method first,
and analysed them by flow cytometry. The
percentage of lymphocytes was 40.02%, monocytes
7.30%, and PMN 51.18%. Then, we mixed the
separated cells with tumour cells labelled with CFSE
at different ratios and incubated them for 48 h at
37°C. The survival rate for tumour cells was
observed and counted by Fluoroskan. 
The confocal microscopy results revealed that
human blood leukocytes possessed direct anti-
tumour activity. Further studies suggested that the
survival rate for tumour cells was the lowest in the
N A549 MCF-7 Hela
Group A 35 0.61 ±0.11 0.37 ±0.13 0.53 ±0.15*
Group B 106 0.64 ±0.13 0.38 ±0.18 0.46 ±0.18
Group C 59 0.65 ±0.11 0.40 ±0.16 0.49 ±0.21
Table I. Comparison analysis of target cells’ survival
rate after leukocyte infiltration in 200 healthy people
of different age groups
Comparing with group B, *P < 0.05
E/T CD3+ CD3+ CD4+ CD3+ CD8+ CD4/CD8 CD3– CD19+ CD3– CD56+
A549 5 : 1 0.107 –0.019 0.172* –0.072 –0.065 –0.096
10 : 1 0.068 0.015 0.084 –0.107 –0.007 –0.111
20 : 1 –0.075 –0.189** 0.073 –0.188** –0.087 0.047
MCF-7 5 : 1 0.178* 0.195** 0.022 0.201** –0.079 –0.211**
10 : 1 0.155* 0.175* –0.011 0.144* –0.053 –0.151*
20 : 1 0.097 0.113 –0.030 0.054 –0.088 –0.079
Hela 5 : 1 0.105 0.110 0.013 0.110 –0.032 –0.159*
10 : 1 0.115 0.093 0.021 0.113 –0.125 –0.208*
20 : 1 0.123 0.074 0.068 0.070 –0.140* –0.210*
*P < 0.05, **P < 0.01
Table II. Correlation analysis between target cell survival rate following leukocyte infiltration in 200 healthy people
and immune function (n = 200)
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condition of a 20 : 1 ratio of effector cells to target
cells. 
We found that the distribution for 200 healthy
people with different anti-tumour ability was
different for different tumour cells. For A549 cells,
among 200 healthy people, the percentage of
healthy people with the strongest anti-tumour
ability was 2%; the percentage of healthy people
with the strongest anti-tumour ability was 30% and
21% for MCF-7 cells and Hela cells, respectively. This
showed that the number of healthy people with the
strongest anti-tumour ability was highest when the
target cells were MCF-7 cells.
The innate immune response is known to play
a critical role in the development of effective anti-
tumour immunity and granulocytes, such as
polymorphonuclear neutrophils (PMNs). As key
mediators of inflammation, they have been suggested
to have the potential to initiate immune response
cascades against tumours. So, we speculated that the
distribution for 200 healthy people with different anti-
tumour ability was related to the anti-tumour effects
of PMN. Many studies have confirmed that the anti-
tumour effects of hyperthermia and BCG are related
to the site of PMN infiltration [9-10]. PMN around the
tumour can kill the tumour by releasing a series of
cytotoxic substances, such as reactive oxygen species,
nitric oxide, lysosome, IL-1, TNF and other cytokines.
PMN was found in vitro to have a certain role in anti-
tumour activity [11-13]. 
Another study showed PMN having close
contacts with injured tumour cells, and activated
PMN may adhere to the surface of tumour cells and
cleave them. At the same time, degranulation of
PMN occurred. In Cui’s research on SR/CR mice, they
did not produce ascites by intraperitoneal injection
of S180 tumour cells. The reason is that PMN of mice
can rapidly reach the periphery of tumour cells and
S180 was surrounded by PMN, macrophage and NK
cells, which formed a rosette [11-12]. By electron
microscopy observation, they found that the
microvilli in the surface of tumour cells reduce and
damage cell membranes, which induce death of
tumour cells. We support the direct anti-tumour
activity mechanism which was observed in human
leukocytes in relation to the above discussion. 
PMN fight tumours not only through the direct
killing of tumour cells, but also through antibody-
dependent cell-mediated cytotoxicity (ADCC) 
[14-15]. Research has shown that early rupture 
of tumour cells has been correlated with 
a PMN-mediated ADCC role. The application of
granulocyte-macrophage colony-stimulating factor
(GM-CSF) can increase the role of PMN in ADCC.
Pre-clinical studies on renal cell carcinoma found
that a united application of anti-epidermal growth
factor receptor, anti-human leukocyte Fc receptor
and myeloid growth factors (such as GM-CSF) may
kill a large number of tumour cells, and PMN is the
effector cell mediating anti-tumour activity.
Moreover, we found that in different age groups
of healthy people the difference in cell survival rate
was significant between group A and group B for
Hela cells (P<0.05). The survival rate for Hela cells
decreased as age increased. This means that the
killing rate for Hela cells increased with an increase
in age of healthy people (P < 0.01). This is not
consistent with Dr Cui’s reports, because the age
of healthy people we chose was between 18 and 
23 years and the average age is 25 ±7.3 years.
Therefore, further study concerning age needs to
be conducted.
Leukocytes of healthy people act differently in
their effect on different tumour cells. Is this related
to their immune function? We analysed the
correlation between target cells’ survival rate after
the infiltration of leukocytes in 200 healthy people
and immune function of healthy people. It showed
that survival of A549, MCF-7 and Hela cells was
correlated with T, B and NK lymphocytes. This was
not the same as the result of Dr Cui, which
demonstrated that NK played an important role in
the destruction of cancer cells [6]. 
In summary, our study suggested that human
blood leukocytes possess direct anti-tumour activity.
The distribution for 200 healthy people with
different anti-tumour ability that was different for
different tumour cells has been found to possibly
be related to the anti-tumour effects of PMN.
According to this, we can choose healthy individuals
with strong anti-tumour ability as anti-tumour
donors according to their distribution with different
anti-tumour ability. Future considerations include
how to validate strong anti-tumour donors from
a crowd of people and how to further activate
innate immune cells and how to avoid allogeneic
transfusion that may lead to rejection. These need
to be addressed in future research work.
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